Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report released on Thursday. The firm set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Price Performance

NYSE:BTX opened at $7.00 on Thursday. The firm has a 50-day moving average of $1.75 and a two-hundred day moving average of $1.28. The stock has a market cap of $411.78 million, a P/E ratio of -3.08 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 1-year low of $6.66 and a 1-year high of $8.31.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.